ArticleStem cell reports2020
Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons.
Article in Stem cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Distinct media requirements for dopaminergic neuron reprogramming from human glia and fibroblasts.Scientific reports · 2026Article
- The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial.Stem cell reports · 2026Article
- A distinct lineage pathway drives parvalbumin chandelier cell fate in human interneuron reprogramming.Science advances · 2026Article
- Three-dimensional co-culturing reveals human stem cell-derived somatostatin interneurons with subclass expression.Stem cell reports · 2025Article
- The history and status of dopamine cell therapies for Parkinson's disease.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- 3D model for human glia conversion into subtype-specific neurons, including dopamine neurons.Cell reports methods · 2024Article
- Rapid and high-purity differentiation of human medium spiny neurons reveals LMNB1 hypofunction and subtype necessity in modeling Huntington's disease.Inflammation and regeneration · 2024Article
- Identification and validation of novel engineered AAV capsid variants targeting human glia.Frontiers in neuroscience · 2024Article
- Miniature-swine iPSC-derived GABA progenitor cells function in a rat Parkinson's disease model.Cell and tissue research · 2023Article
- Roles of Transcription Factors in the Development and Reprogramming of the Dopaminergic Neurons.International journal of molecular sciences · 2022Review
- Reprogramming Glial Cells into Functional Neurons for Neuro-regeneration: Challenges and Promise.Neuroscience bulletin · 2021Review
- Neuronal replacement: Concepts, achievements, and call for caution.Current opinion in neurobiology · 2021Review
- The 2020 Yearbook of Neurorestoratology.Journal of neurorestoratology · 2021Review
- Induced Neurons for Disease Modeling and Repair: A Focus on Non-fibroblastic Cell Sources in Direct Reprogramming.Frontiers in bioengineering and biotechnology · 2021Review
- Restoration of Visual Function and Cortical Connectivity After Ischemic Injury Through NeuroD1-Mediated Gene Therapy.Frontiers in cell and developmental biology · 2021Article
- Direct Conversion of Human Stem Cell-Derived Glial Progenitor Cells into GABAergic Interneurons.Cells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Human glial progenitor cells (hGPCs) are promising cellular substrates to explore for the in situ production of new neurons for brain repair. Proof of concept for direct neuronal reprogramming of glial progenitors has been obtained in mouse models in vivo, but conversion using human cells has not yet been demonstrated. Such studies have been difficult to perform since hGPCs are born late during human fetal development, with limited accessibility for in vitro culture. In this study, we show proof of concept of hGPC conversion using fetal cells and also establish a renewable and reproducible stem cell-based hGPC system for direct neural conversion in vitro. Using this system, we have identified optimal combinations of fate determinants for the efficient dopaminergic (DA) conversion of hGPCs, thereby yielding a therapeutically relevant cell type that selectively degenerates in Parkinson's disease. The induced DA neurons show a progressive, subtype-specific phenotypic maturation and acquire functional electrophysiological properties indicative of DA phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.